<DOC>
	<DOCNO>NCT01929200</DOCNO>
	<brief_summary>This study design evaluate efficacy icotinib adjuvant therapy treat patient . The primary endpoint compare recurrence-free survival 1-year 2-year treatment icotinib .</brief_summary>
	<brief_title>Icotinib Adjuvant Therapy Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation</brief_title>
	<detailed_description>Adjuvant therapy prove effective treating stage II-IIIA non-small-cell lung cancer . However , data treat time adjuvant therapy available . Here conduct randomize , prospective study compare recurrence-free survival 1-year 2-year treatment icotinib EGFR-mutated non-small cell lung cancer patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>The patient sign write informed consent The patient present operable stage IIIIIA nonsmallcell lung cancer 19 21 exon mutation The patient history anticancer therapy include chemotherapy , radiation therapy The patient ' Eastern Cooperative Oncology Group score â‰¤ 02 Patients unresected tumor Wild EGFR type Allergic study drug Patients severe noncancerous disease Patients undergo current administration anticancer therapy , attend clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>